Adaptive Biotechnologies マネジメント
マネジメント 基準チェック /24
Adaptive Biotechnologiesの CEO はChad Robinsで、 Sep2009年に任命され、 の在任期間は 15.17年です。 の年間総報酬は$ 8.90Mで、 7.4%給与と92.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.23%を直接所有しており、その価値は$ 10.77M 。経営陣と取締役会の平均在任期間はそれぞれ5.7年と8.8年です。
主要情報
Chad Robins
最高経営責任者
US$8.9m
報酬総額
| CEO給与比率 | 7.4% |
| CEO在任期間 | 15.2yrs |
| CEOの所有権 | 1.2% |
| 経営陣の平均在職期間 | 5.7yrs |
| 取締役会の平均在任期間 | 8.8yrs |
経営陣の近況
Recent updates
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Oct 05Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$195m |
| Jun 30 2024 | n/a | n/a | -US$213m |
| Mar 31 2024 | n/a | n/a | -US$215m |
| Dec 31 2023 | US$9m | US$663k | -US$225m |
| Sep 30 2023 | n/a | n/a | -US$196m |
| Jun 30 2023 | n/a | n/a | -US$191m |
| Mar 31 2023 | n/a | n/a | -US$195m |
| Dec 31 2022 | US$9m | US$658k | -US$200m |
| Sep 30 2022 | n/a | n/a | -US$221m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$229m |
| Dec 31 2021 | US$9m | US$639k | -US$207m |
| Sep 30 2021 | n/a | n/a | -US$190m |
| Jun 30 2021 | n/a | n/a | -US$171m |
| Mar 31 2021 | n/a | n/a | -US$155m |
| Dec 31 2020 | US$7m | US$597k | -US$146m |
| Sep 30 2020 | n/a | n/a | -US$122m |
| Jun 30 2020 | n/a | n/a | -US$99m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$3m | US$493k | -US$70m |
| Sep 30 2019 | n/a | n/a | -US$62m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$3m | US$423k | -US$46m |
報酬と市場: Chadの 総報酬 ($USD 8.90M ) は、 US市場 ($USD 3.14M ) の同規模の企業の平均を上回っています。
報酬と収益: Chadの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Chad Robins (49 yo)
15.2yrs
在職期間
US$8,904,267
報酬
Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$8.90m | 1.23% $ 10.8m | |
| President & COO | 6.8yrs | US$2.97m | 0.32% $ 2.8m | |
| Co-Founder & Chief Scientific Officer | 15.2yrs | US$8.61m | 0.69% $ 6.1m | |
| Chief Commercial Officer of Immune Medicine | 6.8yrs | US$2.88m | 0.22% $ 1.9m | |
| Founder | no data | データなし | データなし | |
| VP, CFO & Principal Accounting Officer | 3.1yrs | US$1.66m | 0.10% $ 916.6k | |
| Vice President of Investor Relations | no data | データなし | データなし | |
| Senior VP | 5.7yrs | データなし | 0.094% $ 826.4k | |
| Chief People Officer | 5.6yrs | データなし | 0.17% $ 1.5m | |
| Chief Commercial Officer of MRD | 4.3yrs | データなし | 0.17% $ 1.5m | |
| Senior Vice President of MRD BioPharma | 1.2yrs | データなし | データなし |
5.7yrs
平均在職期間
49.5yo
平均年齢
経験豊富な経営陣: ADPTの経営陣は経験豊富で経験豊富です（平均在職期間は5.7年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 15.2yrs | US$8.90m | 1.23% $ 10.8m | |
| Lead Independent Director | 10.9yrs | US$355.00k | 0.093% $ 818.2k | |
| Member of Corporate Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.7yrs | US$330.00k | 0.035% $ 308.1k | |
| Independent Director | 11.8yrs | US$325.00k | 0.051% $ 450.5k | |
| Independent Director | 6.8yrs | US$310.00k | 0.037% $ 322.0k | |
| Member of Corporate Advisory Board | no data | データなし | データなし | |
| Member of Corporate Advisory Board | no data | データなし | データなし | |
| Member of Corporate Advisory Board | no data | データなし | データなし | |
| Member of Corporate Advisory Board | no data | データなし | データなし | |
| Independent Director | 3.7yrs | US$310.00k | 0.038% $ 332.8k |
8.8yrs
平均在職期間
58.5yo
平均年齢
経験豊富なボード: ADPTの 取締役会 は 経験豊富 であると考えられます ( 8.8年の平均在任期間)。